Insertional mutagenesis represents a serious adverse effect of gene therapy with integrating vectors. However, although uncontrolled activation of growth-promoting genes in stem cells can predictably lead to oncological processes, this is far less likely if vector transcriptional activity can be restricted to fully differentiated cells. Diseases requiring phenotypic correction only in mature cells offer such an opportunity, provided that lineage/stage-restricted systems can be properly tailored. In this study, we followed this reasoning to design lentiviral vectors for the gene therapy of chronic granulomatous disease (CGD), an immune deficiency due a loss of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in phagocytes, most often secondary to mutations in gp91 phox . Using self-inactivating HIV1-derived vectors as background, we first expressed enhanced green fluorescent protein (eGFP) from a minimal gp91 phox promoter, adding various natural or synthetic transcriptional regulatory elements to foster both specificity and potency. The resulting vectors were assessed either by transplantation or by lentiviral transgenesis, searching for combinations conferring strong and specific expression into mature phagocytic cells. The most promising vector was modified to express gp91 phox and used to treat CGD mice. High-level restoration of NADPH activity was documented in granulocytes from the treated animals. We propose that this lineage-specific lentiviral vector is a suitable candidate for the gene therapy of CGD.
INTRODUCTION
Gene transfer to hematopoietic stem cells (HSC) is a promising approach for the treatment of a variety of inherited and acquired immunological and hematological disorders, because HSC have the potential to engraft stably and reconstitute all blood cell lineages. Integrating vectors seem most suitable for ensuring the long-term genetic correction of HSC and their progeny, yet they also carry the risk of insertional mutagenesis, a serious adverse effect resulting from transcriptional dysregulations at and around the vector-integration site. This was best exemplified by the occurrence of leukemia in several X-linked severe combined immunodeficient patients, treated by autologous transplantation of HSC transduced with a murine leukemia virus-derived retroviral vector, secondary to the vector-induced activation of the LMO2 proto-oncogene. 1 Although such a sequence of events is to be feared whenever growth-promoting genes are uncontrollably activated in stem cells and early progenitors, the triggering of an oncogenic cascade seems far less likely if transcriptional disturbances only take place in fully differentiated cells. Many genetic diseases of the hematological and immunological system require phenotypic correction in stem cells or early progenitors because the mutation affects, for instance, the genesis of a specific lineage, as for X-severe combined immunodeficiency. However, others such as chronic granulomatous disease (CGD) results in functional impairments that only affect mature cells.
CGD is an immunodeficiency caused by a defect in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (OMIM #306400), the enzyme that produces microbicidal superoxide oxygen radicals, indispensable for degradation of pathogens in phagocytic cells, notably neutrophils. NADPH oxidase is a macromolecular complex comprising of several subunits encoded by four distinct genes. Around 70% of CGD cases are X-linked, resulting from defects in the CYBB gene that encodes the gp91 phox subunit of the complex. 2 CGD patients are highly susceptible to severe bacterial and fungal infection, which most often leads to a fatal outcome during young adulthood.
A recent report described two X-CGD patients treated by autologous transplantation of HSC transduced with a murine leukemia virus-derived retroviral vector-expressing gp91 phox from the spleen focus-forming virus promoter. In both the cases, the clonal expansion of gene-modified cells was observed in the peripheral blood. 2, 3 Furthermore, both subjects showed silencing of the transgene due to methylation of the viral promoter, and myelodysplasia with monosomy 7 as a result of insertional activation of ecotropic viral integration site 1 (Evi1). 4 The spleen focus-forming virus promoter is strong and ubiquitously active, notably inducing high levels of expression in HSCs. 5 Such property is completely dispensable for CGD, in which the functional correction of the underlying defect is required only in differentiated myeloid cells, which have a low proliferative capacity and a short half-life, hence a minimal likelihood of leukemic degeneration. CGD, thus, constitutes an ideal candidate for treatment with transcriptionally restricted vectors.
In this study, we explored this avenue by taking lentiviral vectors as the starting material. 6 The efficiency of this system for gene delivery into HSC has been demonstrated both in tissue culture and in vivo, with the help of various animal models. Furthermore, the autologous transplantation of HSC transduced with a lentiviral vector-expressing ABCD1 was recently used with success for the genetic treatment of Figure 1 Testing a set of phagocyte-specific lentiviral vectors in human HSC and derivatives. (a) Schematic diagram of vectors. All vectors have a self-inactivating configuration, with the 5¢-U3 derived from Rous Sarcoma Virus (RSV), and bear a packaging signal (j,) a Rev-responsive element (RRE), a central polypurine tract with its termination sequence (cPPT/cTS) and a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). The eGFP reporter is transcribed from either the hPGK, or the minimal promoter of the gp91 gene. CMVenh is the minimal enhancer of the CMV promoter. Introns are either derived from the the elongation factor 1 gene (EF1a) or synthetic (Syn. intron). (b) eGFP expression in undifferentiated CD34(+) cells and in myeloid cells. CD34(+) cells isolated from human cord blood were transduced with the different vectors at an multiplicity of infection of 150 (5Â10 7 vg ml À1 ) and left untreated or differentiated with cytokines, and analyzed 7 days later by FACS for eGFP expression into the myeloid CD33(+) and stem CD34(+) fraction. The number indicated are the percentage of cells from the eGFP-positive fraction that are positive or negative for the CD33 or CD34 antigen, respectively. The intensity of the fluorescence of these populations is also provided. Quantitative PCR analyses on the same fractions indicated that for these conditions the average vector copy number was 1. (c) Further phenotyping of cells transduced with the CMVenh/gp91-containing lentiviral vector. CD34+ cells transduced with the hPGK or CMVenhgp91-encoding vector and differentiated with the appropriate cytokines were also FACS analyzed at 7 days posttransduction for the eGFP expression in CD14(+) monocytes, CD11b(+) and CD11c(+) granulocytes and in BDCA4(+) plasmacytoid dendritic cells. Some transduced CD34+ were also differentiated in methycellulose and FACS analyzed 14 days later for eGFP expression into the GpA(+) red cells population. adrenoleukodystrophy in two patients for whom there were no matched HSC donor. 7 Of note, it has been postulated, although so far not unequivocally confirmed, that lentiviral vectors may carry a lower risk of insertional mutagenesis than their murine leukemia virus-based retroviral counterparts, as they tend to integrate in the transcribed region of genes rather than in and around the promoters. [8] [9] [10] [11] We used herein the mouse model to screen a series of lentiviral vector derivatives for their ability to govern the lineagespecific expression of a green fluorescent protein (GFP) transgene in phagocytic cells after transplantation of transduced HSCs or lentivector-mediated transgenesis. This resulted in the identification of a vector that induced strong and specific expression into phagocytic cells. This vector was then modified to express the gp91 phox cDNA, and used to treat CGD mice by autologous transplantation of gene-corrected HSC. The granulocytes of the resulting animals showed high-levels of NADPH activity, which could be stimulated further by interferon induction. We conclude that this vector represents a strong candidate for the gene therapy of human CGD. GP47  SP107  GP91  SP107  GP47  SP146  GP91  SP146  GP91  SP146 CMV enh natural myeloid-specific transcriptional unit. 12 To boost levels of transgene expression, we first added a CMV enhancer (CMVenh) and then either a EF1a or a synthetic intron 13, 14 (Figure 1a) . Vectors containing the strong and ubiquitous human phosphoglycerate kinase promoter (hPGK) promoter served as controls in all experiments. To assess lineage-specific expression, the vectors were initially tested with enhanced GFP (eGFP) as a transgene, because it allows a highly quantitative determination of promoter strength by fluorescenceactivated cell sorting (FACS). For this type of question, the more therapeutically relevant gp91 phox transgene would indeed have been less appropriate. First, immunological methods aimed at detecting the gp91 phox protein (that is, western blot or immunofluorescence) are not reproducibly quantitative. Second, the enzymatic activity of the NADPH oxidase, measurable through an in vitro assay, requires the presence of not only gp91 phox but also of the other subunits of this macromolecular complex, which are not found in all cell lineages. Thus, eGFP was used as a universally expressed and easily detectable transgene for vector design experiments.
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RESULTS

Design
Nbr of provirus
We first investigated the activity of the eGFP-containing lentiviral vectors by transduction of human CD34(+) cells isolated from umbilical cord blood and differentiated ex vivo by cytokine treatment, either in liquid culture during 7 days or in methylcellulose for 14 days, normalizing eGFP levels for proviral vector copy number as assessed by quantitative PCR. Although with the hPGK promoter, strong eGFP expression was observed in all examined cell types, with the gp91 promoter it was restricted to myeloid CD33(+)/CD34(À) cells (Figure 1b) . Further phenotyping of eGFP-positive cells revealed that the gp91 promoter drove preferential expression in phagocytic cells such as CD11b(+) and CD11c(+) granulocytes (most of which are CD14(+) monocytes) and in BDCA4(+) plasmacytoid dendritic cells, whereas it was completely silent in cells of the erythroid lineage ( Figure 1c) . The minimal gp91 promoter induced in itself only low levels of eGFP expression. Adding the CMVenh increased the fluorescence intensity to levels that were only fivefold lower than those obtained with the hPGK promoter, while preserving lineage specificity. In contrast, the presence of introns in the vector had no effect, even though we verified by PCR that they were conserved in more than 50% of the proviruses (data not shown).
In vivo expression of most promising candidates
In vitro experiments pointed to the combination of a gp91 minimal promoter with the CMVenh as most promising for phagoyte-specific gene expression. We thus evaluated the corresponding vector in vivo by transplantation into irradiated mice of ex vivo transduced murine HSC (Sca-1 + , c-Kit + , Lin À/low , referred to as LSK), a protocol relevant for human gene therapy. Three groups of mice (n¼5 for each) were transplanted with LSK cells, respectively, (1) mock transduced or exposed to (2) the control hPGK/eGFP vector or (3) the CMVenh-gp91prom/eGFP vector. At 5 weeks later, the fraction of graft-derived cells in the peripheral blood was quantified by measuring the level of CD45 chimerism, as donors and receivers carried the CD45.1 and CD45.2 haplotypes, respectively. The degree of engraftment was comparable among the three groups, averaging 88.3±2.8%, and it remained stable over time (up to 6 months after the graft).
At 8 weeks posttransplantation, we systematically compared eGFP expression between the different groups in LSK and in all major hematopoietic cell types, sorted from the bone marrow, the spleen and the thymus. Representative results are presented in Figure 2 . Importantly, closely similar results were obtained at a longer time point (3 months post-graft). As observed in vitro (Figure 1) , the combination of a gp91 promoter with the CMVenh was inactive in the erythroid lineage, whereas it led to high expression in differentiated phagocytes (granulocytes and macrophages). There was some leakiness in differentiated B and T cells, but importantly no expression in more primitive LSK cells, or in B or T lymphoid precursors was observed. This point was of particular interest as stem cells and early progenitors are substrates most likely to yield leukemic clones by proto-oncogene activation.
Further improvement of the tissue-specific lentiviral vector and in vivo expression screening by lentivector-mediated transgenesis We explored additional avenues to reinforce the strength and myeloid specificity of expression, first by replacing the ubiquitous CMVenh by synthetic homologs previously generated by random multimerization of cis-acting sequences (PU.1, SP1, AP1, AML-1, C/EBPa transcription factor sites) conferring myeloid-specific transcriptional stimulation, second by testing the promoter of gp47, another subunit of the NADPH oxidase 15 (Figure 3a) . We also evaluated the potential benefit of flanking the provirus with insulator sequences derived from the chicken beta-globin 5¢ DNase I hypersensitive site 4 (cHS4) 16, 17 ( Figure 3a) .
To facilitate the comparative analysis of the resulting vectors, we used lentivector-mediated transgenesis, an approach far less costly than the transplantation of ex vivo transduced LSK cells into irradiated animals. Concentrated vectors were injected in the perivitelline zone of fertilized oocytes before implantation into foster mothers as previously described, 18 and eGFP expression was assessed in hematopoietic cells collected from various compartments of 8-week-old transgene-positive pups, normalizing for vector copy number. A minimum of five transgenic animals was examined from each group, only two of which are illustrated, as all gave comparable results (Figure 3b) . The pattern obtained with the CMVenh/gp91 promoter vector was identical to that observed after LSK transduction/transplantation, validating the use of the transgenesis-based approach. The presence of the chicken globin-derived insulator boosted expression in granulocytes. It also slightly increased the low levels of expression measured in differentiated T cells, although without inducing any detectable transcription in early progenitor and stem cells (Figure 3b ). The two synthetic enhancer SP107 and SP146 were tested within the context of either the gp91 or the gp47 promoters (Figure 3c ). Combining SP107 with the gp47 promoter led to nonspecific expression in all hematopoietic compartments, except for the T lineage. Replacing SP107 by SP146 improved specificity, with no expression neither in the erythroid lineage nor in B-cell progenitors. Nevertheless, the SP107/gp47, the SP107/gp91 and SP146/gp47 configurations, all lead to strong eGFP expression in LSK cells. In contrast, the SP146/gp91 expression pattern closely resembled that obtained with CMVenh/gp91, indicating that the SP146 synthetic enhancer can efficiently replace its CMV counterpart to drive strong and specific expression in phagocytes. Adding the cHS4 insulator in the context of the SP146/gp91 vector further increased the levels of eGFP expression in granulocytes and macrophages, as, for lower numbers of integrants, fluorescence intensity was either equal to or higher than without the insulator. Noteworthy there was still no eGFP expression in the LSK population, or in B-or T-cells progenitors.
The lineage specificity of the SP146/gp91/Hs4 vector was confirmed by transduction of human CD34(+) cells (Figure 4 ). eGFP expression, driven by this vector, was restricted to neutrophils CD11b(+)/ CD15(+) and macrophages CD11b(+)/CD14(+), with a fluorescence intensity close to the one obtained with the hPGK promoter.
The SP146/gp91/Hs4 vector was also tested by engraftment of transduced LSK into irradiated mice ( Figure 5 ). eGFP expression Figure 4 Expression pattern of the SP146gp91cHS4 lentivector in undifferentiated human CD34(+) cells and in myeloid cells. CD34(+) cells isolated from human cord blood were transduced with the different vectors at an multiplicity of infection of 150 (5Â10 7 vg ml À1 ) and left untreated or differentiated with cytokines, and analyzed 7 days later by FACS for eGFP expression into the neutrophils CD11b(+)CD15(+), the macrophages CD11b(+)CD14(+) and stem CD34(+)CD133(+) fraction. The numbers presented are the percentage of eGFP(+)cells in the indicated fraction. The intensity of the fluorescence of these populations is also provided.
patterns, thereby obtained closely, correlated with those obtained by transgenesis, except for a slightly increased leakiness in the B lineage. This is consistent with the natural pattern of gp91 expression, as it was shown that B cells do express functional NADPH oxidase. 19 Restoring gp91 phox function in the CGD mouse model eGFP was replaced by the gp91 phox cDNA in the most promising of the tested lentiviral vectors, using a hPGK promoter-containing vector as a control (Figure 6a ). HSC from gp91 knockout male mice were transduced ex vivo and transplanted into gp91 knockout females. 20 Chimerism and proviral copy numbers were first determined at 5 weeks posttransplantation in the peripheral blood of the recipient animals and remained stable even at 6 months after the graft. At 8 weeks posttransplantation, levels of NADPH enzymatic activity were measured using the standard dihydrorhodamine (DHR) test. 21 The percentage of DHR-positive granulocytes was close to zero in the CGD mice, yet, it markedly increased in all mice transplanted with transduced HSC, although at baseline, none of the myeloid-specific promoter combinations allowed rates of DHR positivity as high as hPGK (Figure 6b) . In order to mimic the setting of an infection, we then treated the mice with poly I:C, an inducer of interferon, and examined 5 days later the percentage of DHR-positive circulating granulocytes. The fraction of DHR-positive cells in recipients of HSC transduced with phagocyte-specific vectors was then comparable to levels observed in the hPGK lentivector-modified animals. Furthermore, when DHR values were normalized for chimerism and vector DNA copy number, the vector containing the SP46 enhancer/gp91 promoter/Hs4 insulators, which already demonstrated the highest level of specificity when assessed with eGFP ( Figure 5 ), was the most efficient at restoring gp91 phox function in granulocytes ( Figure 6 ). On the basis of the ability to restrict transgene expression to mature cells and to provide therapeutically relevant levels of transgene, the SP146/gp91/Hs4 vector, thus, appears as a strong candidate for the genetic treatment of CGD. Second, reintroducing only 15-20% of the normal levels of gp91 protein per cell in deficient myeloid cells results in comparatively much higher levels of oxidant production. Third, because the functional consequences of CGD only affect fully differentiated phagocytic cells, vectors can be designed to carry a low risk of oncogenic transformation of early precursors by insertional mutagenesis. The present study describes the development of a lineage-specific lentiviral vector for the genetic treatment of CGD. Expressing gp91 phox from a transcriptional unit that combined the synthetic SP146 myeloid-specific enhancer and the gp91 promoter in a cassette flanked by Hs4 insulator sequences allowed to restore NADPH production in a very high fraction of circulating granulocytes of CGD mice transplanted with transduced HSC. Parallel testing of this lentiviral vector in a highly sensitive in vivo eGFP expression assay further revealed that it was transcriptionally inactive in all hematopoietic cells, except for mature phagocytes and, to a smaller degree, mature B cells, closely recapitulating the physiological pattern of gp91 phox expression. 23 This vector is, thus, predicted to carry a considerably reduced risk of insertional mutagenesis, compared with more ubiquitously active gene transfer systems, such as ones recently used in a CGD gene therapy clinical trial. 3, 4 Natural regulation of gp91phox may be advantageous for gene therapy in X-CGD than using the recently described synthetic promoter, created by fusion of the myeloid specific proto-oncogene c-fes and Cathepsin G 5¢-flanking regions. 24 Transcriptional targeting is increasingly sought in gene therapy, whether to prevent toxic effects of the transgene product in nonphysiological cellular environments, to limit immune responses linked to its expression in antigen-presenting cells or to avoid the activation of proto-oncogenes in early precursors by insertional mutagenesis in the case of integrating vectors. In this regard, there is mounting evidence that vector inadequate expression in multipotent cells with high proliferation potential is more likely to cause insertional mutagenesis than in more mature cells. 25 Whereas gamma-retroviral vectors have caused T-cell leukemias following transduction of HSC, it has been shown that mature T cells are relatively resistant to transformation by oncogenes. 26 Different strategies can be deployed to achieve this feat, several of which were combined in this study. We first chose the context of a selfinactivating lentiviral vector, the provirus of which is devoid of transcriptional ability per se. We then used a tissue-specific promoter, that of the very gene to be corrected. Comparing the gp91 phox promoter with its gp47 counterpart indeed revealed that the latter showed a prohibitive degree of leakiness, notably in early precursor cells. We further added a synthetic enhancer, previously selected by random oligomerization of cis-acting sequences conferring myeloidspecific transcriptional stimulation. Finally, we flanked the vector with a chicken globin-derived insulator element, the unexpected beneficial effect of which was to boost levels of transgene expression in neutrophils, without any leakage in less mature cells.
DISCUSSION
Interestingly, results obtained by transplantation of ex vivo transduction of LSK cells grafted into irradiated mice were closely reproduced by lentivector-mediated transgenesis. The lower integration site complexity in the transgenic animals and the presence of the provirus from the earliest developmental stages, thus, did not alter its expression pattern. Considering its significantly lower cost, transgenesis, thereby, represents an attractive method for the preclinical screening of lentiviral vectors.
After overcoming some reservation due to the nature of their parental virus, HIV1-derived lentiviral vectors have entered the clinical scene, 7 owing notably to their efficiency at transducing HSC with minimal need for stimulation and to their tendency to integrate within the transcribed regions of genes rather than in and around promoters as their murine leukemia virus counterparts. These features may not suffice in themselves to eliminate completely the risk of insertional mutagenesis, as recently observed in the Cavazzana-Calvo and colleagues study. 27 However, the ability to build highly lineagespecific vectors, as described in the present study, is a very significant step in that direction.
MATERIALS AND METHODS
Lentiviral vector constructs
All vectors were based on the pRRL-cPPT-hPGK-mcs-WPRE vector, derived from the pRRL-cPPT-hPGKeGFP-WPRE construct. 28 The gp91promoter is the natural myeloid-specific promoter. 12 The CMVenh comes from the peGFP-N1 (Clontech, Saint-Germain-en-Laye, France), the synthetic intron from the pMG5 (ref. 29 ) and the EF1a intron from the pWPI vector (http://www. addgene.org). The myeloid-specific enhancer SP107 and SP146 were provided by Senlin Li (Department of Medicine, UTHSCSA, San Antonio, TX, USA). 15 The cHS4 insulator corresponds to the chicken beta-globin 5¢-DNase I-hypersensitive site 4 and was provided by Patrick Salmon (Department of Neuroscience, Faculty of Medicine, University of Geneva, Switzerland). Sequences for all plasmids DNA are available at Addgene (http://www.addgene.org) for all the vectors described.
Cells
The 293T cells, kindly provided by Luigi Naldini (Tiget, Milan, Italy), and HCT116 obtained from ATCC (Manassas, VA, USA) were grown in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal calf serum (Hyclone, Logan, UT, USA), 50 IU ml À1 penicillin and 50 mg ml À1 streptomycin (Invitrogen) at 37 1C in a humidified atmosphere containing 5% CO 2 . CD34+ cells were purified and cultured as previously described. 30 Umbilical cord blood was obtained after uncomplicated births in accordance with the French bioethics laws, which do not require written consent for its collect. Methylcellulose cultures (MethoCult M3434; Stem Cell Technologies, Vancouver, British Columbia, Canada) were prepared according to the manufacturer instructions.
Production and titration of lentiviral vectors
Lentiviral vectors pseudotyped with the vesicular stomatitis G protein were generated by transfection into 293T cells of a packaging construct, pCMVDR8.74, a plasmid producing the vesicular stomatitis G protein envelope (pMD2.G); and the vector itself as previously described. 31 Culture medium was collected at 24, 36 and 48 h, pooled, 0.2 mm filtered, concentrated approximately to 1000-fold by ultracentrifugation, aliquoted and stored at 80 1C, until used. The amount of p24 capsid protein was determined using the HIV-1 p24 Core Profile ELISA (NEN/Perkin-Elmer, Courtaboeuf, France) as described by the manufacturer. Viral titers (infectious particles) were determined by 2-h transductions of 1Â10 5 HCT116 cells with serial dilutions of the vector preparation in a 12-well plate. At 72 h later, cells were analyzed for eGFP expression by FACS, and for non-fluorescent vector, genomic DNA from transduced cells was extracted using a genomic DNA purification kit (Promega Corp., Madison, WI, USA), and the infectious particles titer (IP ml À1 ) was determined by quantitative real-time PCR as described elsewhere. 32 Vector titter obtained from the different constructs are presented in Supplementary 
Hematopoietic progenitor isolation, transduction and transplantation
Donor mice were killed and bones from the hind legs were crushed after removing the muscle and connective tissue. Single-cell suspensions were made by filtering through 40-mm meshes. After bone marrow single-cell suspension was made, Lin-bone marrow was prepared by staining with a cocktail of monoclonal antibodies against the following lineage markers: CD4 (GK1.5), CD8a (53.6.7), CD11b (M1/70), CD19 (1D3), Gr1 (RB6.8C5), Ter119 and NK1.1 (PK136), all conjugated with fluorescein isothiocyanate. Labeled cells were then removed by two consecutive incubations with anti-Rat IgG-coated M450 Dynabeads (Dynal, Invitrogen) at a 10:1 bead-to-target cell ratio. Linenriched cells were subsequently stained with antibodies against CD117 (ckit 2B8, R-phycoerythrin conjugate) and Sca1 (D6, allophycocyanin conjugate). LSK (LinÀ Sca1+ CD117+ cells were sorted on a FACS Vantage flow cytometer (Becton Dickinson, San Jose, CA). LSK cells were then resuspended in StemPRO medium supplemented with L-glutamine (2 mM, GIBCO, Invitrogen), Pen/Strep (100 U ml À1 , GIBCO, Invitrogen), mSCF (50 ng ml À1 ), mTPO (25 ng ml À1 ), mFlt3L (30 ng ml À1 ) and IL-11 (105 U ml À1 ), all purchased from R&D systems (Abingdon, UK) and incubated for 1-2 h at 37 1C. Lentiviral transduction was carried out at 200o multiplicity of infection o500 overnight. For transplantation, 2000-5000 transduced cells per mouse were injected i.v., together with 5Â10 5 total bone marrow cells, into recipient mice that had been lethally irradiated (2Â450 rad, 4 h apart). Genotyping of the CGD graft animals for Y chimerism and number of provirus integrated was performed by quantitative PCR as previously described. 32 
FACS analyses
Peripheral blood samples were taken at the indicated time points by tail vein bleeding, leukocytes were isolated on a Histopaque-1083 (Sigma, Buchs, Switzerland) gradient according to the manufacturer's instructions. Bonemarrow suspensions were prepared as described above. Spleen and thymus were isolated and all cell suspensions were filtered through a 40-mm mesh. The different populations were discriminated by FACS according to the expression of cell surface markers as indicated. The following antibodies were used: CD45.1 (SJL, old Ly5.2, new Ly5.1) eFluorTM 450, CD45.2-PECy5.5, CD117 (ckit 2B8)-PE, CD4 (L3T4)-PECy7 and PECy5, CD8a(Ly-2)-PECy7, CD11b (M1/70)-PECy7 and PECy5 Gr1 (RB6.8C5)-PECy7 and APCAlexa750, Ter119-PECy7 and PECy5, B220/CD45R (RA3-6B2)-PECy7, CD34 (RAM 34)-Alexa 647, Sca1 (D7)-PECy5, IgMtot (II/41)-PE, SAV-APCCy7, CD19-PECy5, CD93 (AA4.1)-APC, CD43 (S7)-biotin, CD71 (R17217)-PE. All monoclonal antibody conjugates were purchased from eBiosciences (Frankfurt Germany) or purified and conjugated in Professor Trumpp's laboratory according to standard protocols. CD11c-PE antibody was purchased from BD Pharmingen (Allschwil, Switzerland). Six-color FACS analysis was performed on a FACS Canto instrument (Becton Dickinson), whereas 7-9 colors were carried out on an LSRII (Becton Dickinson, Heidelberg, Germany). Data were analyzed with FlowJo software (Tree Star, Ashland, OR, USA). The DHR test was performed as previously described 21 with the DHR123 from Invitrogen.
Lentiviral vector-mediated transgenesis
We generated transgenic mice by perivitelline injection of fertilized oocytes, as described previously. 18, 33 Briefly, the hybrid strain B6D2F1 derived from C57BL/6JÂDBA2J mice (Charles River, France) was used as an egg donor. Superovulation was induced by intraperitoneal injection of five B6D2F1 females with 10 IU of pregnant-mare serum (Sigma). At 46 h later, a second intraperitoneal injection was performed with 10 IU of human chorionic gonadotropin (Sigma) before mice were mated with B6D2F1 males. At 16 h later, oocytes were collected, injected in the perivitelline space with a highly concentrated vector stock and kept in culture overnight at 37 1C and 5% CO 2 in KSOM medium (MR-121; Zug, Switzerland). Embryos that had reached the two-cell stage were then placed in the ampulla of foster NMRI mothers (eight embryos per ampulla). Titers of lentiviral vector injected were all up to 1Â10 9 IP ml À1 and with a ratio of infectious particles to physical particles better than 1/1000.
